MedTrace Logo

Drug Interactions Trial of Methoxyethyl Etomidate Hydrochloride

NCT06822166 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2025-02-14

No results posted yet for this study

Summary

Sixty-eight healthy subjects were divided into three sequences: A, B and C. The effects of CYP2C19 inhibitor fluconazole and inducer rifampicin on ET-26-HCl injection were evaluated, and the effects of ET-26-HCl injection on pharmacokinetics of omeprazole and midazolam were evaluated.

Conditions

  • Interaction Drug Food

Interventions

DRUG

rifampicin

rifampicin capsule，600 mg

DRUG

Fluconazole

Fluconazole capsules: 400 mg for the first dose and 200 mg for the remaining doses

DRUG

Omeprazole

Omeprazole enteric-coated capsules: 20 mg

DRUG

midazolam

midazolam injection 0.05 mg/kg was administered intravenously

DRUG

ET-26

the dose is 0.8 mg/kg, single dose, Infusion time was 60seconds ± 5seconds

Sponsors & Collaborators

  • Ahon Pharmaceutical Co., Ltd.

    lead OTHER

Principal Investigators

  • Wei Zhao, Doctor · The First Affiliated Hospital of Shandong First Medical University (Qianfoshan Hospital of Shandong Province)

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-12-04
Primary Completion
2024-01-23
Completion
2024-01-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06822166 on ClinicalTrials.gov